A preclinical study by Amoozgar et al. demonstrated that targeting Tregs with anti-GITR antibodies can relieve resistance to immunotherapy (e.g., anti-PD1) in mouse glioblastoma models[117]. Here, TNFRSF18 is linked to glioblastoma.